Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17^th, 2024 at the Mission Bay Conference Center in San Francisco.

“We are proud to convene the CLIMB Research Symposium, a unique forum for the muscle biology community, including academic researchers and students, to engage in scientific discussion and share innovative research,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As pioneers in the therapeutic applications of muscle biology, we are driven to continuously push the boundaries in the field and advance the understanding and potential treatment of muscle-related diseases and disorders. Through collaboration with academia and industry, we are committed to driving transformative progress to shape the future of muscle biology.”

CLIMB is a one-day research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the understanding and treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of research in the field of muscle biology. Expert speakers include:

• Eric Adler, M.D., FACC, Professor of Medicine, The Czarina and Humberto S. Lopez Chancellors Endowed Chair in Cardiology University of California, San Diego; Chief Medical Officer, Lexeo Therapeutics
• Rachelle H. Crosbie, Ph.D., Professor and Chair, Integrative Biology and Physiology, University of California Los Angeles
• Henk Granzier, Ph.D., Professor, Cellular and Molecular Medicine, University of Arizona College of Medicine Tucson
• Darren Hwee, Ph.D., Senior Director, Pharmacology, Cytokinetics
• Ivan Luptak, M.D., Ph.D., Assistant Professor, Medicine, Boston University Chobanian and Avedisian School of Medicine
• Katie Pollard, Ph.D., L.K. Whittier Director, Gladstone Institute of Data Science and Biotechnology; Professor, Department of Epidemiology and Biostatistics, UC San Francisco; Investigator, Chan Zuckerberg Biohub San Francisco
• Benjamin L. Prosser, Ph.D., Associate Professor of Physiology, Associate Director, Pennsylvania Muscle Institute, Director, Center for Epilepsy and NeuroDevelopmental Disorders, University of Pennsylvania Perelman School of Medicine
• Deepak Srivastava, M.D., President and Senior Investigator, Gladstones Institutes
• Sharif Tabebordbar, Ph.D., Co-Founder and Chief Scientific Officer, Kate Therapeutics
  

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates and our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757